Clinigen's approval of PreemieFort® Enteral Solution in Japan marks a significant milestone in neonatal care. This first of its kind human milk-based product enhances nutrition for vulnerable infants.

Prolacta Bioscience's PreemieFort enteral solution, made entirely from human milk, gets prescription status in Japan for vulnerable infants, a pivotal development in neonatal care.

In a groundbreaking development, Japan has approved Prolacta Bioscience’s human milk fortifiers as prescription medication for fragile infants facing significant health risks.

Japan's Ministry of Health has approved Prolacta Bioscience's human milk-based fortifiers as prescription drugs for vulnerable infants, revolutionizing neonatal care.

Japan’s Ministry of Health, Labour and Welfare (MHLW) Approves PreemieFort® Enteral Solution as Prescription Medicine in the NICU DUARTE, Calif., Feb. 19, 2026 /PRNewswire/ — Prolacta Bioscience® today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved PreemieFort® Enteral Solution, a 100% human milk-based fortifier, as a prescription drug for very low birth weight infants, infants with congenital gastrointestinal disorders or congenital heart diseases, and those recovering from gastrointestinal surgery. This regulatory milestone […]

Clinigen obtained approval for Prolacta’s “PreemieFort® Enteral Solution”, a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the “Nutritional management of neonates and infants presenting with weight gain failure such as very low birth weight (VLBW) infants.” The approval was supported by data from the pivotal Japan-based JASMINE Phase III clinical […]

Prolacta Bioscience has announced that Japan has officially approved its 100% human milk-based fortifiers, marking a new era in neonatal care for vulnerable infants in the NICU.

Prolacta Bioscience has made history as Japan approves its human milk-based fortifiers as prescription drugs for vulnerable infants. This milestone enhances neonatal care.

Japan has made a groundbreaking decision by approving Prolacta Bioscience's PreemieFort® Enteral Solution as a prescription medication, marking a significant advancement in neonatal care.

Japanese Ministry of Health, Labour and Welfare (Ministry of Health, Labour and Welfare) approve PreemieFort® as an enteral solution prescription NICU medical care Duarte, California, February 19, 2026 /PRNewswire/ -- Prolacta Bioscience® Japan's Ministry of Health, Labor and Welfare (MHLW) today announced that it has approved Preemie Fort® Enteral Solution, a 100% human milk-based fortifier, for prescription for very low birth weight infants, infants with congenital gastrointestinal disease or congenital heart disease, and infants recovering from gastrointestinal surgery.

Japan's Ministry of Health, Labour and Welfare (MHLW) Approves PreemieFort® Enteral Solution as Prescription Medicine in the NICU DUARTE, Calif., Feb. 19, 2026 /PRNewswire/ -- Prolacta Bioscience® today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved...

Japan's Ministry of Health, Labour and Welfare (MHLW) Approves PreemieFort® Enteral Solution as Prescription Medicine in the NICU DUARTE, Calif., Feb. 19, 2026 /PRNewswire/ -- Prolacta Bioscience® today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved...

Japan's Ministry of Health, Labour and Welfare (MHLW) Approves PreemieFort® Enteral Solution as Prescription Medicine in the NICU DUARTE, Calif., Feb. 18, 2026 /PRNewswire/ -- Prolacta Bioscience® today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved...

Clinigen obtained approval for Prolacta's "PreemieFort® Enteral Solution", a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the "Nutritional management of neonates and infants presenting with weight gain failure such as very low birth weight...